A Randomized, Open-label, Single Dose, Two-way, Crossover, Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects

The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.

Start Date25 Jan 2026

Sponsor / Collaborator

Huons Co., Ltd.

NCT07301437

/ Not yet recruitingPhase 4IIT

A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.

To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.

Start Date01 Jan 2026

Sponsor / Collaborator-

ChiCTR2500113481

/ Not yet recruitingEarly Phase 1IIT

The exploration of the efficacy and possible mechanisms of paroxetine combined with liraglutide in the treatment of depression associated with obesity.

Start Date28 Nov 2025

Sponsor / Collaborator

Southeast University Affiliated Zhonda Hospital

100 Clinical Results associated with Liraglutide

100 Translational Medicine associated with Liraglutide

100 Patents (Medical) associated with Liraglutide

4,011

Literatures (Medical) associated with Liraglutide

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Mechanisms and therapeutic strategies of ferroptosis in Diabetic-Associated Cognitive Dysfunction: focus on the crosstalk with apoptosis, autophagy, and pyroptosis

Review

Author: Jiang, Yayi ; Zhou, Jianlong ; Yue, Rensong ; Shi, Wenxiang

Diabetes-associated cognitive dysfunction (DACD), a serious central nervous system complication of diabetes mellitus, poses a heavy global burden due to its intricate pathogenesis and lack of effective therapies. Mounting evidence identifies programmed cell death (PCD) as a pivotal driver of DACD progression. This review systematically elaborates on the molecular mechanisms of various PCD modalities (including apoptosis, autophagy, pyroptosis, and ferroptosis) in DACD, with a particular focus on the role of ferroptosis as a core pathogenic mechanism. Hyperglycemia disrupts cerebral iron homeostasis, induces mitochondrial dysfunction and oxidative stress, leading to inhibition of glutathione peroxidase 4 (GPX4) activity and accumulation of lipid peroxides. This cascade ultimately triggers ferroptosis in neurons, glial cells, and the blood-brain barrier, resulting in impaired synaptic plasticity and cognitive decline. Furthermore, the review delineates the complex interactive regulatory network between ferroptosis and other PCD forms (e.g., autophagy, pyroptosis), which can converge into the coordinated cell death program of PANoptosis. Intervention strategies targeting ferroptosis, such as iron chelators (deferoxamine), antioxidants (N-acetylcysteine), GPX4 activators, natural products (resveratrol, curcumin), repurposed traditional medicines (liraglutide, metformin), and non-pharmaceutical interventions (exercise, electroacupuncture), have demonstrated significant potential in improving cognitive function in preclinical models. This review aims to provide novel insights into the pathophysiology of DACD and establish a theoretical foundation for developing precise therapeutic strategies centered on targeting ferroptosis.

01 Jun 2026·Journal of Translational Autoimmunity

Liraglutide prevents lupus-associated diffuse alveolar hemorrhage via inhibiting lymphocyte infiltration and promoting macrophage M2 polarization

Article

Author: Long, Hai ; Li, Duo ; Wu, Haijing ; Yang, Ming ; He, Liting ; Luo, Xin ; Jiang, Li

Objectives:

This study aimed to explore the prophylactic and therapeutic role of liraglutide for lupus-associated diffuse alveolar hemorrhage (DAH).

Methods:

A lupus-associated DAH model was established in 6-8-week-old female C57BL/6 mice via intraperitoneal injection of 0.5 mL pristane. Mice were randomized to receive daily intraperitoneal injections of either saline or liraglutide (2 mg/kg/day), starting either 14 days before or on the day of pristane injection, and continuing until 14 days post-injection. Body weight and blood glucose were monitored. Serum levels of anti-dsDNA, ANA, total IgM and IgG were quantified using ELISA. Lung tissues were collected for histopathological analysis with H&E and Prussian blue staining, respectively, characterization of different types of immune cells infiltration with flow cytometry (t-SNE for subset dimensionality reduction) and immunofluorescence, and quantification of protein levels with Western blot.

Results:

Liraglutide significantly alleviated pulmonary hemorrhage, as evidenced by reduced lung wet weight, incidence of lung hemorrhage, pulmonary hemosiderin-laden macrophages, and total serum IgG, without affecting body weight or glucose. Mechanistically, liraglutide treatment reduced pulmonary infiltration of multiple T and B lymphocyte subsets (e.g., CD4⁺, CD8⁺, B220⁺), while concurrently increasing alveolar macrophages and promoting M2 macrophage polarization. The phenotypic shift was demonstrated by increased M2 cell numbers, elevated CD206 expression, and downregulation of M1 marker CD86 and upregulation of M2 marker CD163 as confirmed at the protein level.

Conclusion:

Liraglutide treatment effectively ameliorates lupus-associated DAH, potentially through modulation of T cells, B cells, and macrophages polarization, offering a novel prophylactic and therapeutic strategy for this fatal complication of lupus.

01 May 2026·Biomaterials advances

Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption

Article

Author: Fatahi, Yousef ; Sharifzadeh, Mohammad ; Dinarvand, Rassoul ; Esfandyari-Manesh, Mehdi ; Shams, Narges ; Amini, Mohsen

Oral administration of peptide-based drugs offers improved patient compliance compared to injectable formulations. However, this route is hindered by several physiological barriers like enzymatic degradation, poor intestinal permeability, and low absorption in the gastrointestinal tract. To address these challenges, a novel virus-mimicking nanocarrier was developed for the oral delivery of liraglutide. Hollow mesoporous silica nanoparticles (HMSN) were synthesized via a co-condensation method and subsequently functionalized with a positively charged cell-penetrating peptide (CPP; KLPVM) to facilitate transcellular transport, and with negatively charged hyaluronic acid (HA) to enhance mucus penetration and enable receptor-mediated targeting. Liraglutide was efficiently encapsulated within HMSN matrix, achieving an encapsulation efficiency of 96.16% and a drug loading of 19.23%. In vitro release studies showed pH-responsive behavior, with limited release under acidic gastric conditions (7%) and sustained release at near-neutral intestinal pH (77% over 12 h). Cellular uptake studies revealed enhanced internalization of the HMSN-CPP@HA (98.1%), predominantly via caveolae-mediated endocytosis. Ex vivo intestinal permeability studies further confirmed improved transmucosal transport, with permeability increasing from 34.4% for MSNs to 97.6% for HMSN-CPP@HA. Pharmacodynamic evaluation in streptozotocin-induced diabetic rat models showed that oral administration of liraglutide-loaded virus-mimicking HMSNs resulted in a 50.98% reduction in fasting blood glucose and a 14.6% decrease in body weight over 28-day period. These outcomes were comparable to those achieved via subcutaneous liraglutide administration (62.7% and 19.2% respectively). These findings suggest that HMSN-CPP@HA preserve the biological activity of liraglutide during gastrointestinal transit, enhance intestinal absorption, and mimic viral translocation mechanisms, representing a promising platform for non-invasive oral delivery of peptide drugs.

362

News (Medical) associated with Liraglutide

28 Jan 2026

·www.idorsia.com

Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America

Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026 Idorsia Ltd (SIX: IDIA) announces an exclusive license and supply agreement with EMS S.A., Brazil’s largest privately-owned pharmaceutical company, to bring QUVIVIQ™ (daridorexant) to patients across Latin America. This partnership marks another milestone in Idorsia’s mission to make QUVIVIQ available worldwide. Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented: “We are very excited to join forces with EMS, a market leader with exceptional commercial reach and expertise. This collaboration is a strategic step forward in our global expansion, ensuring that patients in Latin America will soon have access to our innovative treatment for insomnia – the only medication to have shown improvement on daytime functioning and treat insomnia as a 24-hour disorder. Together, we aim to transform the nights and days for millions of people struggling with this condition.” Under the licensing and supply agreement, EMS will be responsible for the registration and commercialization of QUVIVIQ in Latin America. The filing of a regulatory dossier with ANVISA to obtain marketing authorization in Brazil took place in 2025. Idorsia is entitled to receive: Total milestone compensation of USD 20 million for the execution of the agreement, first filing and launch of QUVIVIQ; Supply price plus double-digit royalties on net sales in Brazil and Mexico; Shared milestone payments due to EMS and royalties by sub-licensees in other Latin America countries. QUVIVIQ – a different kind of insomnia treatment Insomnia affects millions in Latin America, yet current treatments are often associated with next-day drowsiness, risk of dependence, and withdrawal symptoms – leaving a clear unmet need for safer, effective alternatives. QUVIVIQ, discovered by Idorsia, works differently from traditional hypnotics. By selectively blocking orexin receptors, it regulates overactive wake signaling without broadly suppressing brain activity. Its optimized pharmacokinetics promote restorative sleep throughout the entire night, reducing morning sleepiness and improving daytime functioning. Clinical trials published in The Lancet Neurology demonstrated that daridorexant significantly improved sleep onset, sleep maintenance, and self-reported total sleep time at 25mg and 50mg doses compared to placebo. Daridorexant 50 mg also demonstrated a highly significant improvement in daytime functioning compared to placebo. Global availability QUVIVIQ is already marketed in the US, Canada, and multiple European countries, and is available in Japan, Hong Kong, and China through strategic partnerships. In addition, it was recently approved by the Israeli Ministry of Health in Israel, where Idorsia has a license agreement with CTS. The EMS collaboration reinforces Idorsia’s commitment to making QUVIVIQ a global brand. Notes to the editor About insomnia Insomnia is defined as a combination of dissatisfaction with sleep and a significant negative impact on daytime functioning. Dissatisfaction with sleep refers to the difficulty to initiate and/or maintain sleep on at least three nights per week for at least three months, despite adequate opportunity to sleep. Insomnia is a condition of overactive wake signaling and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia. Insomnia as a disorder is quite different from a brief period of poor sleep, and it can take its toll on both physical and mental health. It is a persistent condition with a negative impact on daytime functioning. Idorsia’s research has shown that poor-quality sleep can affect many aspects of daily life, including the ability to concentrate, mood, and energy levels. The goals of managing insomnia are to improve sleep quality and quantity, as well as daytime functioning. Current recommended treatment of insomnia includes sleep hygiene recommendations, cognitive behavioral therapy and pharmacotherapy. About EMS EMS is the largest pharmaceutical company in Brazil, market leader for 20 consecutive years, and part of Grupo NC. With more than 60 years of history and over 10,000 employees, it operates in the segments of medical prescriptions, generics, branded medicines, OTC, and non-retail, manufacturing products for virtually all areas of medicine. The company has production units in Hortolândia (SP), where its advanced R&D Center and modern solid medication packaging plant are located; in Jaguariúna (SP); in Brasília (DF); and in Manaus (AM), operating Novamed, one of the largest solid medication factories in the world. It is also present in Serbia with the pharmaceutical company Galenika and in Italy with the Monteresearch laboratory. Following a solid path of innovation and internationalization of its products and consolidation as a global powerhouse, EMS inaugurated in 2024 Brazil’s first peptide factory, capable of producing GLP-1 analogs such as liraglutide and semaglutide for obesity and type 2 diabetes treatment, serving both domestic and international markets. With operations in 56 countries, EMS conducts one of the largest numbers of clinical studies in Brazil and holds approximately 100 patents granted or under review worldwide. About Idorsia The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact Investor & Media Relations Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 58 844 10 10 investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF

License out/inDrug Approval

27 Jan 2026

·nanexa.com

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

27 January, 2026 - Regulatory Download attachment Nanexa’s atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections. Significantly smoother plasma concentration curve could mitigate many common side effects of GLP-1 drugs. Less frequent dosing and improved adherence are key selling points for the next generation of GLP-1s, and reinforce Nanexa’s ability to secure new commercial partnerships. Nanexa AB today announces exceptional preclinical results for its long-acting semaglutide formulation developed using the company’s proprietary PharmaShell® drug delivery platform. PharmaShell encases active pharmaceutical ingredients at the atomic level in a highly protective, extremely thin film coating (approximately 30 nm thick) of slow-dissolving non-toxic inorganic oxides. Recent preclinical studies demonstrate an extraordinary pharmacokinetic (PK) profile, indicating a very low ratio between the maximum and minimum plasma concentration over the dosing interval following once-monthly subcutaneous administration. The plasma concentration is significantly more stable than that typically achieved with weekly administration of the marketed product Wegovy® (semaglutide). Breakthrough PK Profile with Potential to Reduce Gastrointestinal Side Effects A key hallmark of the new formulation is its low initial peak – a feature considered critical in reducing gastrointestinal (GI) adverse events commonly associated with GLP-1 therapies. By avoiding the sharp plasma concentration spikes often linked to nausea and other GI symptoms, Nanexa’s formulation may offer a more tolerable initiation and maintenance profile for patients. The preclinical results show clear dose-linearity, and significantly improved bioavailability compared with Nanexa’s earlier liraglutide formulations. Improved tolerability is strongly linked to improved adherence, which is a key issue associated with GLP-1 therapies. Strategic Shift: From Liraglutide to Semaglutide With these highly encouraging preclinical findings, Nanexa is shifting its development focus from liraglutide to semaglutide, reflecting the substantial therapeutic and commercial opportunity for long-acting GLP-1 treatments. The advancement of this semaglutide program builds directly on the clinical Phase 1 data from Nanexa’s liraglutide program, presented in 2025, which provided key insights into PharmaShell® performance in humans. Those findings enabled refined modelling, improved formulation strategies, and faster advancement for Nanexa toward clinical readiness for semaglutide. “These latest results represent a major milestone for Nanexa,” said David Westberg, CEO of Nanexa. “Demonstrating such a long release profile and low ratio between the maximum and minimum plasma concentration for monthly administration is exceptional and highlights how powerful the PharmaShell® technology can be for complex molecules like semaglutide. We are excited about this data which will strengthen our position to secure commercial partnerships.” For additional information, please contact: David Westberg – CEO, Nanexa AB (publ) Phone: +46 70 942 83 03 Email: david.westberg@nanexa.se www.nanexa.com Richard Hayhurst – Co-founder, 59 North Communications Phone: +447711 821527 Email: richard.hayhurst@59north.bio The company’s Certified Adviser is Tapper Partners AB. About Nanexa AB (publ) Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company’s proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of ‘super generic’ formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others. Nanexa develops its own products and also has collaboration agreements with several pharma companies, including the latest license and option agreement with Moderna. Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA). Attachments Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

Phase 1License out/inClinical Result

16 Jan 2026

·endpoints.news

European regulators recommended 38 novel drugs in 2025, 15 fewer than the FDA

The European Medicines Agency recommended 104 medicines for approval in 2025, the second-highest number in the past 15 years, according to a report the agency published Thursday. Of the positive recommendations last year, 38 were for new active substances — novel molecules, as opposed to reformulations or generics, for instance — according to the report. That figure markedly lags the 53 new treatments greenlit by the FDA in 2025. The total number was second only to the 114 drugs recommended in 2024. “If you look back over the past 15 years, you will see the number waxes and wanes, but there was a big dip during Covid-19,” EMA chief medical officer Steffen Thirstrup said in a press briefing on Thursday. “Some of what we saw [in 2024] was…a wave of things that had been postponed and protracted during Covid-19, and 104 is still a very high number of approvals from a European perspective.” Several new products were approved in the US last year but are still awaiting European authorization. These include Milestone Pharmaceuticals’ Cardamyst, approved in the US in December for an arrhythmia disorder called paroxysmal supraventricular tachycardia. Milestone has submitted an application in the EU for the drug under the name Tachymist, but a decision is not expected until the first quarter of 2027, showing just how long the delay between the two regulators can be. At least one product was approved in Europe but not in the US, however. The European agency recommended Novo Nordisk’s fixed-dose combination of insulin icodec and semaglutide for type 2 diabetes in September, and it was approved in Europe as Kyinsu in November. US approval of Kyinsu is not imminent. The FDA rejected insulin icodec due to manufacturing concerns in 2024. Novo has since resubmitted insulin icodec in the US, but will have to wait for that decision before filing the fixed-dose combination. As a combination of approved drugs, Kyinsu would not count as a novel medicine, however. Endocrinology was the most popular therapeutic area for medicine approvals in Europe last year. The EMA recommended 29 products for endocrine disorders, including three new treatments. These were Bayer’s Lynkuet for menopause symptoms, Sanofi’s Teizeild for type 1 diabetes and Amgen’s Tepezza for thyroid eye disease. Looking to the year ahead, the EMA said it expects continued innovation in weight management and diabetes. The agency has received the first application for a generic version of Novo Nordisk’s older GLP-1 agonist product liraglutide for both indications. Meanwhile, its safety committee is also looking into possible interactions between the drug class and contraceptive pills.

Drug Approval

100 Deals associated with Liraglutide

External Link

KEGG	Wiki	ATC	Drug Bank
-	Liraglutide	A10BJ02	DB06655

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	United States	Novo Nordisk, Inc.	23 Dec 2014
Overweight	United States	Novo Nordisk, Inc.	23 Dec 2014
Diabetes Mellitus, Type 2	European Union	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	Iceland	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	Liechtenstein	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	Norway	Novo Nordisk A/S	30 Jun 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cerebrovascular Disorders	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Chronic heart failure	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Coronary Disease	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Peripheral Vascular Diseases	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Polycystic Ovary Syndrome	Phase 3	United States	Novo Nordisk A/S	26 Sep 2018
Binge-Eating Disorder	Phase 3	United States	Novo Nordisk A/S	29 Sep 2017
Prader-Willi Syndrome	Phase 3	Netherlands	Novo Nordisk A/S	17 Aug 2015
Hypertension	Phase 3	Greece	-	09 Sep 2014
Cardiovascular Diseases	Phase 3	United Kingdom	Novo Nordisk A/S	16 Dec 2013
Diabetes Mellitus, Type 1	Phase 3	United States	Novo Nordisk A/S	01 Nov 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01794143 (GRADE, CTgov)	Phase 3	Diabetes Mellitus, Type 2	7,850	Glargine Insulin (Glargine Insulin U-100)	ftsnespaiu(mtpqqgnctz) = axiwntfszb sjsaymiuvh (qcrpseixqn, geguopseff - texlsydalf) View more	-	10 Feb 2026
				Glimepiride (Glimepiride)	ftsnespaiu(mtpqqgnctz) = lguzvhmint sjsaymiuvh (qcrpseixqn, sldrwxbmjf - iqewmdwlcs) View more
NCT04122716 (Pubmed \| Sports Med)	Phase 3	Obesity	193	Liraglutide (Exercise)	kngsipgbgc(yahrgwmgkt) = idfuacneja zmrhubsgqu (dvkcrlaxpn, 0.5 - 5.5)	Positive	24 Jan 2026
				Liraglutide alone	limpfkyslt(nqsyqijsoe) = txodmakdye xezipbxigz (pguqedgukb )
NCT03948347 (LAMP, Pubmed \| JAMA Intern Med) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Ischemic Attack, Transient \| Acute Ischemic Stroke	636	Liraglutide	vamxzgrtag(ogewgwgzqx) = klrlaifqbp mmhpaqarco (xmprqdbxys ) View more	Positive	03 Nov 2025
				Control	vamxzgrtag(ogewgwgzqx) = rohhvjtusg mmhpaqarco (xmprqdbxys ) View more
NCT03260881 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Coronary Artery Disease	38	liraglutide (Study Group)	cqiflyipjm(crpsrbxult) = pbbnqqmapa lwtbgbwdwd (bvqeizdkve, 0.60) View more	-	08 Jul 2025
				placebo (Control Group)	cqiflyipjm(crpsrbxult) = pavxdppdqs lwtbgbwdwd (bvqeizdkve, 2.3) View more
NCT02516657 (CTgov)	Phase 3	Diabetes Mellitus, Type 1	5	Liraglutide	ijbxfsbjbb(ipwzvuwzth) = uffnzdtibl cdszpycinx (jzwwicurzg, 35) View more	-	20 Apr 2025
NCT04881110 (STARDUST, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Peripheral Arterial Disease	60	Liraglutide (Liraglutide Group)	thgzgbiyjc(xlyxpyhtow) = tjolybwrmd grtqrgblqi (tmrmlhmsuf, 5.9) View more	-	03 Mar 2025
				Control (Control Group)	thgzgbiyjc(xlyxpyhtow) = ookruhvvss grtqrgblqi (tmrmlhmsuf, 4.8) View more
ASCO_GU2025	Phase 3	Prostatic Cancer	-	GLP-1 receptor agonists (GLP-1RAs)	kubtrgzwby(lhfnmhjfwc) = mmfitfedqv yvftardjjd (tldovpfxip )	Negative	13 Feb 2025
				Placebo/non-GLP-1 RA regimens	kubtrgzwby(lhfnmhjfwc) = zftzbpxhss yvftardjjd (tldovpfxip )
Pubmed Manual	Not Applicable	Overweight \| Obesity	15,491	Tirzepatide 15 mg once weekly	cpfafwklen(tbseghtawl) = iaeczqmgza whendmccud (bfemmvjcyg )	Positive	07 Jan 2025
				Semaglutide 2.4 mg once weekly	cpfafwklen(tbseghtawl) = syhnyyjoix whendmccud (bfemmvjcyg )
NCT02098395 \| NCT01836523 (ADJUNCT ONE and ADJUNCT TWO, Pubmed \| J Diabetes Sci Technol)	Phase 3	Diabetes Mellitus, Type 1 C-peptide	-	Liraglutide 1.8 mg	rmzuhkbspk(fhcxkvgmob) = srzjnbtgmn svztrzqprk (fjtbsahybn ) View more	-	24 Dec 2024
				Liraglutide 1.2 mg	rmzuhkbspk(fhcxkvgmob) = qsgexthmdn svztrzqprk (fjtbsahybn ) View more
NCT06439056 (NEWS)	Phase 1	Diabetes Mellitus, Type 2	3	利拉鲁肽-NEX-22A	utxhpjvsql(qwavvatzwa) = Clinical results have reached the endpoint wxtimibhks (hlkbuioshi ) View more	Positive	22 Nov 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis